Home › Breast Cancer › Georgia › Sandy Springs
Breast Cancer clinical trials in Sandy Springs, GA
3 studies for Breast Cancer are looking for participants at sites in and around Sandy Springs (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RecruitingPhase 3
- Clinical Trial Site, Marietta · 10 mi away
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
RecruitingPhase 3
- Research Site, Marietta · 10 mi away
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RecruitingPhase 3
- Northwest Georgia Oncology Centers PC - Marietta, Marietta · 10 mi away
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY134 studies
- Houston, TX126 studies
- Boston, MA111 studies
- Nashville, TN80 studies
- Los Angeles, CA72 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Durham, NC63 studies
- Queens, NY63 studies
- Chicago, IL58 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Other studies in Sandy Springs
- Non-Small Cell Lung Cancer9 studies
- Steatotic Liver Disease6 studies
- Obesity6 studies
- Overweight5 studies
- Type 2 Diabetes5 studies
- Heart Failure5 studies
- Cardiovascular Disease5 studies
- Depression4 studies
- Stroke4 studies
- Hidradenitis Suppurativa3 studies
- Coronary Artery Disease3 studies
- Multiple Sclerosis3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.